An in vitro experimental study of the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli
- PMID: 31647407
- DOI: 10.1099/jmm.0.001061
An in vitro experimental study of the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli
Abstract
Background. This study was conducted to understand the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli.Methods. Fifty urinary tract multidrug-resistant E. coli isolates that were known biofilm producers were studied. The MIC was determined using the agar dilution method for amikacin, ciprofloxacin, meropenem and fosfomycin. The fractional inhibitory concentration was determined for the combination of antibiotics followed by a time-kill assay. A tissue culture plate method was used to study the effect of the combination of antibiotics on biofilm formation.Results. The MICs of the isolates tested ranged from 0.25 to 32 µg ml-1 for fosfomycin, 1 to 1024 µg ml-1 for ciprofloxacin, 4 to 1024 µg ml-1 for amikacin, and 0.25 to 512 µg ml-1 for meropenem. The combination of fosfomycin with meropenem showed 68 % synergy, fosfomycin with amikacin 58 % synergy and fosfomycin with ciprofloxacin 6 % synergy. The combination also reduced the MIC of each antibiotic and none showed an antagonistic effect. Biofilm inhibition was best observed with the combination of fosfomycin with meropenem.Conclusion. The combination of fosfomycin with amikacin and fosfomycin with meropenem yielded a high percentage of synergy alongside an increased capacity to reduce biofilm formation when compared to combination with ciprofloxacin against multidrug-resistant E. coli. Fosfomycin in combination with other classes of antimicrobial agents has potential beneficial effects.
Keywords: FIC; MDR E.coli; MIC; biofilm; fosfomycin combination.
Similar articles
-
[Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].Mikrobiyol Bul. 2023 Jul;57(3):365-377. doi: 10.5578/mb.20239930. Mikrobiyol Bul. 2023. PMID: 37462301 Turkish.
-
Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant.Diagn Microbiol Infect Dis. 2020 Sep;98(1):115098. doi: 10.1016/j.diagmicrobio.2020.115098. Epub 2020 Jun 1. Diagn Microbiol Infect Dis. 2020. PMID: 32603974
-
Evaluation of in vitro activity of fosfomycin, and synergy in combination, in Gram-negative bloodstream infection isolates in a UK teaching hospital.J Med Microbiol. 2022 Apr;71(4). doi: 10.1099/jmm.0.001524. J Med Microbiol. 2022. PMID: 35476672
-
Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa.Antimicrob Agents Chemother. 2013 Aug;57(8):3628-39. doi: 10.1128/AAC.00359-13. Epub 2013 May 20. Antimicrob Agents Chemother. 2013. PMID: 23689709 Free PMC article. Review.
-
Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.Pharmacotherapy. 2019 Nov;39(11):1077-1094. doi: 10.1002/phar.2326. Epub 2019 Oct 14. Pharmacotherapy. 2019. PMID: 31487056 Review.
Cited by
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Efficacy of Fosfomycin against Planktonic and Biofilm-Associated MDR Uropathogenic Escherichia coli Clinical Isolates.Trop Med Infect Dis. 2022 Sep 8;7(9):235. doi: 10.3390/tropicalmed7090235. Trop Med Infect Dis. 2022. PMID: 36136646 Free PMC article.
-
Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.Antimicrob Agents Chemother. 2023 May 1;65(5):e02213-20. doi: 10.1128/AAC.02213-20. Epub 2021 Mar 8. Antimicrob Agents Chemother. 2023. PMID: 33685903 Free PMC article.
-
Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients - a tertiary care centre experience.Access Microbiol. 2020 Sep 3;2(10):acmi000163. doi: 10.1099/acmi.0.000163. eCollection 2020. Access Microbiol. 2020. PMID: 33195977 Free PMC article.
-
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.Antibiotics (Basel). 2020 Aug 10;9(8):500. doi: 10.3390/antibiotics9080500. Antibiotics (Basel). 2020. PMID: 32785114 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
